The Impact of Co-morbidity on Outcomes in Men with Advanced Prostate Cancer Treated with Chemotherapy (Docetaxel)
Side effects, or what are known as co-morbidities, often discourage men who have metastatic prostate cancer from continuing with chemotherapy (docetaxel). The question often asked is there a relationship between having side effects and the [...]
ZYTIGA – Potential Dosing Error – IMPORTANT
Error in ZYTIGA® Beginning Your Treatment Brochure It has come to Malecare's attention that the dosing schedule for ZYTIGA® (abiraterone acetate) is incorrectly described in the ZYTIGA® Beginning Your Treatment brochure. Please destroy the ZYTIGA® Beginning Your Treatment brochure and the ZYTIGA® Resource Kit. It contains [...]
The Power Of A Cancer Diagnosis And How We Fail To Respond Positively
For cancer, January 2016 has been an unusual month. This January, cancer has managed to take the lives of three world renowned entertainers; David Bowie, Alan Rickman and Terry Wogan. Examining their deaths, we see [...]
PET/CT Scans More Sensitive Than CT and Bone Scans For Detecting Metastatic Prostate Cancer
According to an article in the Journal of Nuclear Medicine, researchers compared a PET/CT scan using the radiotracer F-18 DCFBC to conventional imaging modalities — an expanded Tc-99m-methylene diphosphonate (MDP) bone scan and contrast-enhanced CT [...]
Combination Chemotherapy And ADT In Hormone Sensitive Prostate Cancer Betters Survival and the Quality Of Life
There is a paradigm shift happening around us in the clinical care of men with metastatic hormone-sensitive prostate cancer. We now know that survival is better when docetaxel chemotherapy is added to androgen-deprivation therapy (ADT), [...]
PSA Values For Prostate Cancer Diagnosis In Men Who Are HIV Positive Might Be Different Than For Men Who Are Not HIV Positive
In General the use of a PSA value in excess of 4.0 µg/L is considered a clinical indicator for men at risk for prostate cancer. But, is this a good prognostic indicator in men who [...]